MCID: PST029
MIFTS: 40

Postmenopausal Atrophic Vaginitis

Categories: Reproductive diseases

Aliases & Classifications for Postmenopausal Atrophic Vaginitis

MalaCards integrated aliases for Postmenopausal Atrophic Vaginitis:

Name: Postmenopausal Atrophic Vaginitis 12 15 74
Atrophic Vaginitis 12 77 17
Senile Vaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11968
ICD9CM 36 627.3
SNOMED-CT 69 52441000
ICD10 34 N95.2
UMLS 74 C0156409

Summaries for Postmenopausal Atrophic Vaginitis

Disease Ontology : 12 A vaginitis that occurs in postmenopausal women and is characterized by vaginal atrophy secondary to estrogen deficiency.

MalaCards based summary : Postmenopausal Atrophic Vaginitis, also known as atrophic vaginitis, is related to vaginitis and osteoporosis. An important gene associated with Postmenopausal Atrophic Vaginitis is PRLR (Prolactin Receptor), and among its related pathways/superpathways are Prolactin Signaling Pathway and Transcription Ligand-dependent activation of the ESR1/SP pathway. The drugs Apricot and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotypes are adipose tissue and behavior/neurological

Wikipedia : 77 Atrophic vaginitis is inflammation of the vagina as a result of tissue thinning due to not enough... more...

Related Diseases for Postmenopausal Atrophic Vaginitis

Diseases related to Postmenopausal Atrophic Vaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 vaginitis 30.1 AR ESR1 ESR2
2 osteoporosis 29.3 AR ESR1 ESR2 SHBG
3 lipid-rich carcinoma 10.2 ESR1 PRLR
4 progesterone-receptor positive breast cancer 10.2 ESR1 ESR2
5 progesterone resistance 10.2 ESR1 ESR2
6 47, xxy 10.2 AR SHBG
7 androgen insensitivity, partial 10.2 AR SHBG
8 dental fluorosis 10.2 ESR1 ESR2
9 endometriosis of ovary 10.2 ESR1 ESR2
10 alopecia, androgenetic, 1 10.2 AR SHBG
11 oncocytic breast carcinoma 10.2 AR ESR1
12 endometrial squamous cell carcinoma 10.2 AR ESR1
13 apocrine adenocarcinoma 10.2 AR ESR1
14 peritoneal benign neoplasm 10.2 AR ESR1
15 diffuse peritoneal leiomyomatosis 10.2 AR ESR1
16 myoma 10.2 ESR1 OXT
17 androgenic alopecia 10.2 AR SHBG
18 breast adenoid cystic carcinoma 10.1 AR ESR1
19 sebaceous gland disease 10.1 AR SHBG
20 complete androgen insensitivity syndrome 10.1 AR SHBG
21 androgen insensitivity syndrome 10.1 AR SHBG
22 endometrial disease 10.1 ESR1 OXT
23 transsexualism 10.1 AR ESR2
24 sexual disorder 10.1 OXT SHBG
25 testicular germ cell cancer 10.1 AR ESR2
26 hypoadrenalism 10.1 POMC SHBG
27 endometritis 10.1 ESR1 OXT
28 prostatic hypertrophy 10.1 AR ESR1
29 fetal erythroblastosis 10.1 POMC SHBG
30 testicular leydig cell tumor 10.1 ESR1 POMC
31 postpartum depression 10.1 ESR1 OXT
32 chromophobe adenoma 10.1 POMC PRLR
33 estrogen-receptor negative breast cancer 10.1 AR ESR1
34 female breast cancer 10.1 AR ESR1
35 sporadic breast cancer 10.0 ESR1 ESR2
36 uterine anomalies 10.0 ESR1 OXT
37 breast cancer 10.0
38 lobular neoplasia 10.0 ESR1 ESR2 PRLR
39 estrogen excess 10.0 ESR1 ESR2 SHBG
40 ovarian disease 10.0 ESR1 ESR2 SHBG
41 withdrawal disorder 10.0 AR POMC
42 rh isoimmunization 10.0 OXT POMC
43 primary pigmented nodular adrenocortical disease 10.0 ESR1 POMC
44 ductal carcinoma in situ 10.0 AR ESR1
45 hyperandrogenism 10.0 POMC SHBG
46 pain agnosia 10.0 OXT POMC
47 agnosia 10.0 OXT POMC
48 male reproductive system disease 9.9 AR ESR2 SHBG
49 hyperprolactinemia 9.9 POMC PRLR SHBG
50 prostatic hyperplasia, benign 9.9 AR ESR2 SHBG

Comorbidity relations with Postmenopausal Atrophic Vaginitis via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Female Stress Incontinence
Hypertension, Essential Hypothyroidism
Osteoporosis

Graphical network of the top 20 diseases related to Postmenopausal Atrophic Vaginitis:



Diseases related to Postmenopausal Atrophic Vaginitis

Symptoms & Phenotypes for Postmenopausal Atrophic Vaginitis

MGI Mouse Phenotypes related to Postmenopausal Atrophic Vaginitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.93 AR ESR1 ESR2 OXT POMC PRLR
2 behavior/neurological MP:0005386 9.91 AR ESR1 ESR2 OXT POMC PRLR
3 endocrine/exocrine gland MP:0005379 9.88 AR ESR1 ESR2 OXT POMC PRLR
4 integument MP:0010771 9.85 AR ESR1 ESR2 OXT POMC PRLR
5 neoplasm MP:0002006 9.65 AR ESR1 ESR2 POMC PRLR
6 nervous system MP:0003631 9.63 AR ESR1 ESR2 OXT POMC PRLR
7 limbs/digits/tail MP:0005371 9.62 AR ESR1 ESR2 PRLR
8 renal/urinary system MP:0005367 9.35 AR ESR1 ESR2 OXT POMC
9 reproductive system MP:0005389 9.02 AR ESR1 ESR2 OXT PRLR

Drugs & Therapeutics for Postmenopausal Atrophic Vaginitis

Drugs for Postmenopausal Atrophic Vaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Apricot Approved Phase 4
2
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
3 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Estrogens, Conjugated (USP) Phase 4,Phase 3,Phase 1,Not Applicable
6 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Protective Agents Phase 4
9 Immunologic Factors Phase 4,Phase 3
10 Adjuvants, Immunologic Phase 4,Phase 3
11 Viscosupplements Phase 4
12
Polyestradiol phosphate Approved Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
13
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
14
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
15
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
16 Estradiol 3-benzoate Phase 3,Phase 2,Phase 1,Not Applicable
17 Estradiol 17 beta-cypionate Phase 3,Phase 2,Phase 1,Not Applicable
18 Contraceptive Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Pycnogenols Phase 3
20
Megestrol Phase 3 3562-63-8 19090 3080587
21 Contraceptives, Oral Phase 3
22 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
23 Appetite Stimulants Phase 3
24 Central Nervous System Stimulants Phase 3
25 DHEA (Dehydroepiandrosterone) Phase 3
26 Aromatase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
27 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
28 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
29 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
30
Echinacea Approved, Experimental Phase 1, Phase 2
31
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
32
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
33
Calcium polycarbophil Approved Phase 2 126040-58-2
34
Loperamide Approved Phase 2 53179-11-6 3955
35
Caffeine Approved Phase 2 58-08-2 2519
36
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 58-22-0, 481-30-1 6013 10204
37
Testosterone enanthate Approved Phase 1, Phase 2 315-37-7 9416
38
Testosterone undecanoate Approved, Investigational Phase 1, Phase 2 5949-44-0
39
Methyltestosterone Approved Phase 1, Phase 2 58-18-4 6010
40
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
41 Omega 3 Fatty Acid Phase 2
42 Gotu Kola Phase 1, Phase 2
43 Oxytocics Phase 2
44 Progestins Phase 2
45 Gastrointestinal Agents Phase 2
46 Cathartics Phase 2
47 Psyllium Phase 2
48 Antidiarrheals Phase 2
49 Calcium, Dietary Phase 2
50 Laxatives Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Vaginal and Urinary Microbiome Trial Unknown status NCT02869165 Phase 4 Premarin vaginal cream;Apricot kernel oil
2 Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis Completed NCT02014428 Phase 4 Placebo
3 Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
4 Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis Completed NCT03294538 Phase 3 Estrace® Cream;Generic Estradiol Cream;Vehicle Cream
5 Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis Completed NCT00137371 Phase 3 PVC (daily for 21 days, 7 days off);PVC (twice weekly)
6 Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms Completed NCT00108849 Phase 3 estradiol, 10 mcg
7 A Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%) to Estrace® Cream (0.01%) in Postmenopausal Females With Atrophic Vaginitis Completed NCT02995694 Phase 3 Estradiol;Placebos;Reference
8 A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis Completed NCT02195986 Phase 3 Estradiol Vaginal Cream, 0.01%;Estrace® 0.01% cream;Placebo Vaginal Cream
9 Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial Completed NCT00464971 Phase 3 estradiol, 25 mcg
10 Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis Completed NCT00465192 Phase 3 estradiol, 10 mcg;estradiol, 25 mcg;placebo
11 Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis Completed NCT00431132 Phase 3 estradiol, 10 mcg
12 Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo Completed NCT01779947 Phase 3 Estradiol Vaginal Tablets 10 mcg;placebo
13 S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer Completed NCT00005975 Phase 3 Megestrol Acetate 20mg/day;Megestrol Acetate 40 mg/day;Megestrol Acetate Placebo 20 mg/day;Megestrol Acetate Placebo 40 mg/day
14 Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause Completed NCT02013544 Phase 3 Placebo;Prasterone (DHEA)
15 Topical DHEA Against Vaginal Atrophy Completed NCT01846442 Phase 3 Placebo;DHEA (0.25%);DHEA (0.5%);DHEA (1.0%)
16 Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy Completed NCT01358760 Phase 3 Placebo;DHEA;DHEA
17 DHEA Against Vaginal Atrophy - 3-Month Efficacy Study Completed NCT01256684 Phase 3 Placebo;DHEA;DHEA
18 DHEA Against Vaginal Atrophy - Safety Study of 12 Months Completed NCT01256671 Phase 3 DHEA
19 The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse Completed NCT00803335 Phase 3 Vaginal conjugated estrogen cream 0.5gm;Vaginal conjugated estrogen cream 1.0gm
20 Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer Not yet recruiting NCT03740945 Phase 3 Placebo;Prasterone (DHEA)
21 A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis Terminated NCT00816556 Phase 3 Estriol;Estradiol valerate;Vanicream Lite
22 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Completed NCT02150525 Phase 2
23 Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV Completed NCT02313545 Phase 1, Phase 2 IZN-6NVS Cream
24 An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy Completed NCT02497547 Phase 2 Oxytocin;Placebo
25 Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women Completed NCT02162160 Phase 2 Placebo
26 Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy Recruiting NCT02460302 Phase 2 Vaginal progesterone;Placebo
27 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Recruiting NCT01984138 Phase 2 ESTRING;Replens
28 Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. Suspended NCT01122342 Phase 1, Phase 2 Testosterone propionate
29 The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis Unknown status NCT02733731 Phase 1 Chinese Herbal Compound Ointment;Estriol
30 Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis Completed NCT00167921 Phase 1 Premarin® Vaginal Cream;Premarin® oral tablets
31 Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients Completed NCT01370551 Phase 1 Gynoflor
32 Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis Completed NCT01486979 Phase 1 estradiol, 10 mcg;estradiol, 25 mcg
33 Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis Completed NCT01085877 Phase 1 estradiol, 25 mcg;estradiol, 25 mcg
34 Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis Recruiting NCT03898401 Phase 1
35 Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency Completed NCT01507454 estradiol, 25 mcg
36 Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy Completed NCT02691936 Not Applicable Estrogens, Conjugated (USP)
37 Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness Completed NCT02029053 Early Phase 1
38 A Review on the Outcome of Patient Managed in Postmenopausal Bleeding Clinic Recruiting NCT03382145
39 Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen Active, not recruiting NCT00984399 Not Applicable Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist

Search NIH Clinical Center for Postmenopausal Atrophic Vaginitis

Genetic Tests for Postmenopausal Atrophic Vaginitis

Anatomical Context for Postmenopausal Atrophic Vaginitis

MalaCards organs/tissues related to Postmenopausal Atrophic Vaginitis:

42
Breast

Publications for Postmenopausal Atrophic Vaginitis

Articles related to Postmenopausal Atrophic Vaginitis:

(show all 13)
# Title Authors Year
1
Comparison of the effect of hyaluronic acid and estrogen on atrophic vaginitis in menopausal women: A systematic review. ( 30798700 )
2019
2
Application of conjugated estrogen cream in the treatment of postmenopausal atrophic vaginitis. ( 30463825 )
2018
3
17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. ( 30358715 )
2018
4
Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17beta-estradiol vaginal tablets. ( 16108394 )
2005
5
Vaginal estrogen preparations for relief of atrophic vaginitis. ( 15152956 )
2004
6
Atrophic vaginitis. A treatable cause of vaginal dryness. ( 14646897 )
2002
7
Treatment of atrophic vaginitis in postmenopausal women with micronized estradiol cream--a follow-up study. ( 458255 )
1979
8
Treatment of atrophic vaginitis. ( 458258 )
1979
9
Estrogen therapy in atrophic vaginitis. ( 5480497 )
1970
10
Atrophic vaginitis treated with nitrofurazone-estrogen vaginal suppositories. ( 5727825 )
1968
11
NITROFURAZONE-ESTROGEN VAGINAL SUPPOSITORIES IN THE TREATMENT OF ATROPHIC VAGINITIS. ( 14341031 )
1965
12
Geriatric office practice. Pessaries; atrophic vaginitis, gynecologic aspects of osteoporosis. ( 14488538 )
1962
13
ATROPHIC vaginitis. ( 21027203 )
1946

Variations for Postmenopausal Atrophic Vaginitis

Expression for Postmenopausal Atrophic Vaginitis

Search GEO for disease gene expression data for Postmenopausal Atrophic Vaginitis.

Pathways for Postmenopausal Atrophic Vaginitis

GO Terms for Postmenopausal Atrophic Vaginitis

Biological processes related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.8 AR ESR1 ESR2 OXT POMC
2 cell-cell signaling GO:0007267 9.5 AR ESR2 POMC
3 steroid hormone mediated signaling pathway GO:0043401 9.43 AR ESR1
4 intracellular receptor signaling pathway GO:0030522 9.37 AR ESR1
5 transcription, DNA-templated GO:0006351 9.26 AR ESR1
6 intracellular estrogen receptor signaling pathway GO:0030520 9.16 ESR1 ESR2
7 transcription initiation from RNA polymerase II promoter GO:0006367 9.13 AR ESR1 ESR2
8 mammary gland alveolus development GO:0060749 8.62 AR ESR1

Molecular functions related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.71 AR ESR1 ESR2 SHBG
2 enzyme binding GO:0019899 9.61 AR ESR1 ESR2
3 estrogen receptor activity GO:0030284 9.37 ESR1 ESR2
4 steroid hormone receptor activity GO:0003707 9.33 AR ESR1 ESR2
5 androgen binding GO:0005497 9.32 AR SHBG
6 estrogen response element binding GO:0034056 9.26 ESR1 ESR2
7 nuclear receptor activity GO:0004879 9.13 AR ESR1 ESR2
8 steroid binding GO:0005496 8.92 AR ESR1 ESR2 SHBG

Sources for Postmenopausal Atrophic Vaginitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....